EN 
ES About us
Peruvian company focused on improving access to healthcare
through innovative products and strategic services
Who We Are
20 years connecting Innovation, Quality, and Partnerships to transform Healthcare in Peru
We are a Peruvian company with a solid track record in the management of pharmaceutical products and services. Since 2005, we have brought innovative therapeutic solutions to the healthcare system, including medicines for rare and orphan diseases. We operate under the highest standards, holding certifications such as Good Storage Practices (GSP), Good Distribution Practices (GDP), and Good Pharmacovigilance Practices (GVP), among others, while our partners also comply with Good Manufacturing Practices (GMP), ISO certifications, and more—guaranteeing the quality, efficacy, and safety of the products we market. Committed to expanding access to cutting-edge treatments and ensuring the institutional supply of high-impact therapies, today we continue to be the strategic ally for those who strive to transform healthcare in Peru..
Our corporate philosophy defines us as
leaders in the Peruvian and Latin
American markets.
Our Vision
To be a leading company in the Peruvian healthcare sector, recognized for its management capacity, constant innovation, and commitment to access to high-value therapies, generating trust among healthcare professionals as well as the institutions we serve.
Our Mision
To continuously contribute to improve the quality of life of patients in Peru through the responsible and timely import and distribution of innovative, high-quality medicines. We work in close collaboration with healthcare institutions and professionals, ensuring access to therapeutic solutions that have a positive impact on medical care.
Our Values
Regulatory compliance: We respect laws and authorities in all our actions.
- Punctuality and respect: We value everyone’s time and dignity.
- Customer focus: We are committed to meeting your needs and satisfaction.
- Social responsibility: We act ethically with awareness of our community impact.
- Continuous innovation: We constantly improve through development and new ideas.
- Training and perseverance: We promote ongoing learning and consistent effort.
Our achievements motivate
and drive us forward.
Our work marks a turning point in public management,
laying the foundations for current national programs.
We introduced Crysvita®, the first treatment for XLH with guaranteed public access. We enabled over 72 pediatric transplants using unique cell therapy technology in Peru. For 7 years, we supplied factors VIII, IX, and von Willebrand for Hemophilia A and B to MINSA and EsSalud, marking a turning point in public management of this condition.
Burosumab
In 2022, we introduced Crysvita® to the Peruvian market, the first and only monoclonal antibody in the world approved for the treatment of X-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO), marking a milestone in the care of rare diseases in the country.
Transplants
More than 72 haploidentical transplants in pediatric patients with unrelated donors were made possible thanks to our high-precision magnetic cell separation products—a unique technology in the country—specialized for leukemias and aplastic anemia syndromes.
Supplying
For more than 7 years, we were pioneers in supplying coagulation factors for the prophylactic treatment of hemophilia A and B in public institutions such as the Ministry of Health (MINSA) and EsSalud, among others. Our work marked a turning point in the public management of this condition, laying the foundations for today’s national programs.
Our Partners
Driving innovation and transforming
healthcare in Peru and Latin America
Please enter your inquiry
Please fill out the form below with your information and your company's details. Then, if you wish, leave us a comment and click the 'Submit' button. You are important to us and will be attended to as soon as possible.
